The VII Young Researchers Awards are an initiative by the AstraZeneca Foundation under the motto of «People who change lives», to support the growth and consolidation of young scientific talent in Spain.
The molecular and cellular underpinnings of intercellular communication in deadly prostate cancer are the focus of research led by CIC bioGUNE and researcher Arkaitz Carracedo is in charge of overseeing LetalCHAT.
A project coordinated and led by Arkaitz Carracedo, Ikerbasque research Professor in the Cancer Cell Signaling and Metabolism Laboratory at CIC bioGUNE – member of BRTA -, has just received the Young Researchers award in the category ‘Oncology, Precision Medicine and Immunoncology’, awarded by the AstraZeneca Foundation. This is an initiative that, in its seventh edition and under the motto “People who change lives», recognizes and promotes the development and consolidation of young scientific talent in Spain.
The project ‘Deciphering the molecular and cellular bases of intercellular communication in lethal prostate cancer: LetalCHAT’ has received 225,000 euros, an amount that will help improve the quality of life of thousands of patients. The Vall d’Hebron Institute of Oncology (VHIO), the Vall d’Hebron University Hospital and the Carlos III State Public Sector Foundation (CNIO) also collaborate in this project.
The Young Researchers Awards of the AstraZeneca Foundation seek to promote research between groups from different autonomous communities, structured in a network research project, which facilitates the obtaining of results and generates greater scientific knowledge by promoting synergies between the different Investigation groups.
The project coordinator, Dr. Arkaitz Carracedo explained the reasons for this research: “This project is based on an emerging clinical need in oncology: there is a small group of patients with prostate cancer who present metastases. At the time of diagnosis, and whose disease presents alarming aggressiveness and mortality. We propose to unravel the mechanism underlying this aggressiveness with the most modern experimental and technological approaches, and through the creation of a young and highly synergistic team made up of clinical, computational and experimental researchers.”
Likewise, Dr. Carracedo added that “The recognition of the AstraZeneca Foundation represents an exciting challenge for us for two main reasons. On the one hand, the Foundation is the promoter of the fact that we have structured a young research team around an ambitious question. The participation of 3 centers of excellence such as CIC bioGUNE, VHIO and CNIO is proof of the highly competitive ingredients of the proposal. On the other hand, with this funding, the AstraZeneca Foundation will be a catalyst for a research project that may mean the creation of new groups and lines of research in oncology in the near future.”